Actively Recruiting
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Led by The First Affiliated Hospital of Soochow University · Updated on 2026-03-19
32
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Soochow University
Lead Sponsor
J
Jining Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
CONDITIONS
Official Title
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with AML who are not suitable for intensive chemotherapy
- Age 18 to 59 years with ECOG physical status score of 2 or 3
- Expected survival of at least 3 months
- Presence of severe cardiac, lung, liver, or kidney disease as specified
- No radiotherapy, other treatments, or stem cell transplant within 4 weeks before enrollment
- Comorbidities making intensive chemotherapy unsuitable
- Ability and willingness to sign informed consent
- Refusal of intensive chemotherapy but willing to accept non-intensive therapy
- Patients 60 years or older meeting WHO diagnosis for AML not suitable for intensive chemotherapy
You will not qualify if you...
- History of myeloproliferative neoplasms including myelofibrosis, thrombocythemia, polycythaemia vera, chronic granulocytic leukemia with or without BCR-ABL1 translocation, AML or acute promyelocytic leukemia with BCR-ABL1
- FLT3 mutation patients treated with targeted agents unless discontinued
- Less than 50% reduction of blasts after VA regimen
- Active central nervous system involvement
- Prior treatment with chidamide
- Uncontrolled active infections or organ hemorrhage
- Pregnant or lactating women
- Participation in other clinical trials within 3 months before VAC regimen
- Other malignant tumors
- Uncontrolled mental disorders
- Any other condition judged inappropriate by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
Research Team
S
Sheng-Li Xue, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here